Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1976 Oct;31(5):493–506. doi: 10.1136/thx.31.5.493

Immunology of bronchial carcinoma.

D A Evans
PMCID: PMC470466  PMID: 793085

Full text

PDF
493

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W. In vitro assays of cell-mediated immunity to human solid tumors: problems of quantitation, specificity, and interpretation. J Natl Cancer Inst. 1975 Oct;55(4):745–748. doi: 10.1093/jnci/55.4.745. [DOI] [PubMed] [Google Scholar]
  2. Baldwin R. W., Pimm M. V. B.C.G. suppression of pulmonary metastases from primary rat hepatomata. Br J Cancer. 1974 Nov;30(5):473–476. doi: 10.1038/bjc.1974.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baldwin R. W., Pimm M. V. BCG immunotherapy of a rat sarcoma. Br J Cancer. 1973 Oct;28(4):281–287. doi: 10.1038/bjc.1973.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnes E. W., Farmer A., Penhale W. J., Irvine W. J., Roscoe P., Horne N. W. Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung. Cancer. 1975 Jul;36(1):187–193. doi: 10.1002/1097-0142(197507)36:1<187::aid-cncr2820360117>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  5. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer (first of two parts). N Engl J Med. 1974 Jun 20;290(25):1413–1420. doi: 10.1056/NEJM197406202902506. [DOI] [PubMed] [Google Scholar]
  6. Boddie A. W., Jr, Holmes E. C., Roth J. A., Morton D. L. Inhibition of human leukocyte migration in agarose by kcl extracts of carcinoma of the lung. Int J Cancer. 1975 May 15;15(5):823–829. doi: 10.1002/ijc.2910150514. [DOI] [PubMed] [Google Scholar]
  7. Bomford R. Active specific immunotherapy of mouse methylcholanthrene induced tumours with Corynebacterium parvum and irradiated tumour cells. Br J Cancer. 1975 Nov;32(5):551–557. doi: 10.1038/bjc.1975.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bowen J. G., Baldwin R. W. Tumour-specific antigen related to rat histocompatibility antigens. Nature. 1975 Nov 6;258(5530):75–76. doi: 10.1038/258075a0. [DOI] [PubMed] [Google Scholar]
  9. Braeman J., Deeley T. J. Radiotherapy and the immune response in cancer of the lung. Br J Radiol. 1973 Jun;46(546):446–449. doi: 10.1259/0007-1285-46-546-446. [DOI] [PubMed] [Google Scholar]
  10. Cardozo E. L., Harting M. C. Immunologic behaviour before and during cytostatic treatment in bronchus carcinoma. Oncology. 1971;25(6):520–527. doi: 10.1159/000224603. [DOI] [PubMed] [Google Scholar]
  11. Currie G. A. Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br J Cancer. 1972 Jun;26(3):141–153. doi: 10.1038/bjc.1972.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. DELORME E. J., ALEXANDER P. TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTES. Lancet. 1964 Jul 18;2(7351):117–120. doi: 10.1016/s0140-6736(64)90126-6. [DOI] [PubMed] [Google Scholar]
  13. Dellon A. L., Rogentine G. N., Jr, chretien P. B. Prolonged survival in bronchogenic carcinoma associated with HL-A antigens W-19 and HL-A5: a preliminary report. J Natl Cancer Inst. 1975 Jun;54(6):1283–1286. doi: 10.1093/jnci/54.6.1283. [DOI] [PubMed] [Google Scholar]
  14. Ducos J., Migueres J., Colombies P., Kessous A., Poujoulet N. Lymphocyte response to P.H.A. in patients with lung cancer. Lancet. 1970 May 23;1(7656):1111–1112. doi: 10.1016/s0140-6736(70)92775-3. [DOI] [PubMed] [Google Scholar]
  15. EVANS C. A., GORMAN L. R., ITO Y., WEISER R. S. Antitumor immunity in the Shope papilloma-carcinoma complex of rabbits. I. Papilloma regression induced by homologous and autologous tissue vaccines. J Natl Cancer Inst. 1962 Aug;29:277–285. [PubMed] [Google Scholar]
  16. Edwards F. R., Whitwell F. Use of BCG as an immunostimulant in the surgical treatment of carcinoma of the lung. Thorax. 1974 Nov;29(6):654–658. doi: 10.1136/thx.29.6.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. FINNEY J. W., BYERS E. H., WILSON R. H. Studies in tumor autoimmunity. Cancer Res. 1960 Apr;20:351–356. [PubMed] [Google Scholar]
  18. Fairley G. H. Immunity to malignant disease in man. Br Med J. 1969 May 24;2(5655):467–473. doi: 10.1136/bmj.2.5655.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fakhri O., Hobbs J. R. Overcoming some limiting factors in tumour immunotherapy. Br J Cancer. 1973 Jul;28(1):1–5. doi: 10.1038/bjc.1973.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ferluga J., Allison A. C. Observations on the mechanism by which T-lymphocytes exert cytotoxic effects. Nature. 1974 Aug 23;250(5468):673–675. doi: 10.1038/250673a0. [DOI] [PubMed] [Google Scholar]
  21. Fidler I. J. Immune stimulation-inhibition of experimental cancer metastasis. Cancer Res. 1974 Mar;34(3):491–498. [PubMed] [Google Scholar]
  22. Frost M. J., Rogers G. T., Bagshawe K. D. Extraction and preliminary characterization of a human bronchogenic carcinoma antigen. Br J Cancer. 1975 Apr;31(4):379–386. doi: 10.1038/bjc.1975.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Golstein P., Blomgren H., Svedmyr E. A., Wigzell H. On T-cell-mediated cytotoxicity. Transplant Proc. 1973 Dec;5(4):1441–1445. [PubMed] [Google Scholar]
  24. Golub S. H., O'Connell T. X., Morton D. L. Correlation of in vivo and in vitro assays of immunocompetence in cancer patients. Cancer Res. 1974 Aug;34(8):1833–1837. [PubMed] [Google Scholar]
  25. Griffiths J. D., McKinna J. A., Rowbotham H. D., Tsolakidis P., Salsbury A. J. Carcinoma of the colon and rectum: circulating malignant cells and five-year survival. Cancer. 1973 Jan;31(1):226–236. doi: 10.1002/1097-0142(197301)31:1<226::aid-cncr2820310130>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  26. Han T., Takita H. Immunologic impairment in bronchogenic carcinoma: a study of lymphocyte response to phytohemagglutinin. Cancer. 1972 Sep;30(3):616–620. doi: 10.1002/1097-0142(197209)30:3<616::aid-cncr2820300304>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  27. Hellström I., Hellström K. E., Sjögren H. O., Warner G. A. Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer. 1971 Jan 15;7(1):1–16. doi: 10.1002/ijc.2910070102. [DOI] [PubMed] [Google Scholar]
  28. Hellström I., Hellström K. E., Warner G. A. Increase of lymphocyte-mediated tumor-cell destruction by certain patient sera. Int J Cancer. 1973 Sep 15;12(2):348–353. doi: 10.1002/ijc.2910120205. [DOI] [PubMed] [Google Scholar]
  29. Herberman R. B., Oldham R. K. Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. J Natl Cancer Inst. 1975 Oct;55(4):749–753. doi: 10.1093/jnci/55.4.749. [DOI] [PubMed] [Google Scholar]
  30. Hodson M. E., Turner-Warwick M. Autoantibodies in patients with bronchial carcinoma. Thorax. 1975 Aug;30(4):367–370. doi: 10.1136/thx.30.4.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hoebeke J., Franchi G. Influence of tetramisole and its optical isomers on the mononuclear phagocytic system. Effect on carbon clearance in mice. J Reticuloendothel Soc. 1973 Sep;14(3):317–323. [PubMed] [Google Scholar]
  32. Hollinshead A. C., Stewart T. H., Herberman R. B. Delayed-hypersensitivity reactions to soluble membrane antigens of human malignant lung cells. J Natl Cancer Inst. 1974 Feb;52(2):327–338. doi: 10.1093/jnci/52.2.327. [DOI] [PubMed] [Google Scholar]
  33. Hughes N. R. Serum concentrations of G, A, and M immunoglobulins in patients with carcinoma, melanoma, and sarcoma. J Natl Cancer Inst. 1971 May;46(5):1015–1028. [PubMed] [Google Scholar]
  34. Irie K., Irie R. F. Immunological suppression of the occurrence of spontaneous mammary tumours in C3H/He mice. Nature. 1971 Sep 10;233(5315):133–134. doi: 10.1038/233133b0. [DOI] [PubMed] [Google Scholar]
  35. Israel L., Bouvrain A., Cros-Decam J., Mugica J. Contribution à l'étude des phénomènes d'immunité cellulaire chez les cancéreux pulmonaires avant traitement palliatif ou chirurgical. Poumon Coeur. 1968;24(3):339–350. [PubMed] [Google Scholar]
  36. Israel L. Cell-mediated immunity in lung cancer patients: data, problems, and propositions. Cancer Chemother Rep 3. 1973 Mar;4(2):279–281. [PubMed] [Google Scholar]
  37. Israel L., Mawas C., Bouvrain A., Mannoni P., Sors C. Etude de l'hypersensibilité retardée à la tuberculine chez 130 cancéreux adultes. Effets du B.C.G. Pathol Biol. 1967 Jun-Jul;15(11):597–601. [PubMed] [Google Scholar]
  38. Israël L., Halpern B. Le Corynebacterium parvum dans les cancers avancés. Premiére évaluation de l'activité thérapeutique de cette immuno-stimuline. Nouv Presse Med. 1972 Jan 1;1(1):19–23. [PubMed] [Google Scholar]
  39. KUPER S. W. EXFOLIATIVE CYTOLOGY IN THE DIAGNOSIS OF CANCER OF THE BRONCHUS. J Clin Pathol. 1963 Sep;16:399–404. doi: 10.1136/jcp.16.5.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Khadzhiev S., Kavaklieva-Dimitrova Ia. Lechenie bol'nykh rakom bronkha vodno-solevym ékstraktom BtsZh. Vopr Onkol. 1971;17(8):51–57. [PubMed] [Google Scholar]
  41. Kirchner H., Blaese R. M. Pokeweed mitogen-, concanavalin A-, and phytohemagglutinin-induced development of cytotoxic effector lymphocytes. An evaluation of the mechanisms of T cell-mediated cytotoxicity. J Exp Med. 1973 Oct 1;138(4):812–824. doi: 10.1084/jem.138.4.812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Krant M. J., Manskopf G., Brandrup C. S., Madoff M. A. Immunologic alterations in bronchogenic cancer. Sequential study. Cancer. 1968 Apr;21(4):623–631. doi: 10.1002/1097-0142(196804)21:4<623::aid-cncr2820210414>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  43. Kuo T. T., Rosai J., Tillack T. W. Immunological studies of membrane glycoproteins isolated from human breast carcinomas. Int J Cancer. 1973 Sep 15;12(2):532–542. doi: 10.1002/ijc.2910120225. [DOI] [PubMed] [Google Scholar]
  44. LYTTON B., HUGHES L. E., FULTHORPE A. J. CIRCULATING ANTIBODY RESPONSE IN MALIGNANT DISEASE. Lancet. 1964 Jan 11;1(7324):69–71. doi: 10.1016/s0140-6736(64)91390-x. [DOI] [PubMed] [Google Scholar]
  45. Laurence D. J., Stevens U., Bettelheim R., Darcy D., Leese C., Turberville C., Alexander P., Johns E. W., Neville A. M. Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma. Br Med J. 1972 Sep 9;3(5827):605–609. doi: 10.1136/bmj.3.5827.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Law L. L., Henriksen O., Appella E. Tumour rejection properties of solubilised TSTA from an SV40-induced neoplasm. Nature. 1975 Sep 18;257(5523):234–235. doi: 10.1038/257234a0. [DOI] [PubMed] [Google Scholar]
  47. Lee A. K., Rowley M., Mackay I. R. Antibody-producing capacity in human cancer. Br J Cancer. 1970 Sep;24(3):454–463. doi: 10.1038/bjc.1970.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Lee Y. T., Sparks F. C., Eilber F. R., Morton D. L. Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer. Cancer. 1975 Mar;35(3):748–755. doi: 10.1002/1097-0142(197503)35:3<748::aid-cncr2820350330>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  49. Lejeune F. J. Role of macrophages in immunity, with special reference to tumour immunology. A review. Biomedicine. 1975 Jan;22(1):25–34. [PubMed] [Google Scholar]
  50. Levin A. G., Cunningham M. P., Steers A. K., Miller D. G., Southam C. M. Production of 19S and 7S antibodies by cancer patients. Clin Exp Immunol. 1970 Dec;7(6):839–849. [PMC free article] [PubMed] [Google Scholar]
  51. Levy J. G., Whitney R. B., Smith A. G., Panno L. The relationship of immune status to the efficacy of immunotherapy in preventing tumour recurrence in mice. Br J Cancer. 1974 Oct;30(4):289–296. doi: 10.1038/bjc.1974.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Lewis M. G., Loughridge L. W., Phillips T. M. Immunological studies in nephrotic syndrome associated with extrarenal malignant disease. Lancet. 1971 Jul 17;2(7716):134–135. doi: 10.1016/s0140-6736(71)92305-1. [DOI] [PubMed] [Google Scholar]
  53. Lo Gerfo P., Krupey J., Hansen H. J. Demonstration of an antigen common to several varieties of neoplasia. N Engl J Med. 1971 Jul 15;285(3):138–141. doi: 10.1056/NEJM197107152850302. [DOI] [PubMed] [Google Scholar]
  54. Loughridge L. W., Lewis M. G. Nephrotic syndrome in malignant disease of non-renal origin. Lancet. 1971 Feb 6;1(7693):256–258. doi: 10.1016/s0140-6736(71)90999-8. [DOI] [PubMed] [Google Scholar]
  55. Marx J. L. Tumor Immunology (I): The Host's Response to Cancer. Science. 1974 May 3;184(4136):552–556. doi: 10.1126/science.184.4136.552. [DOI] [PubMed] [Google Scholar]
  56. McKenzie D., Colsky J., Hetrick D. L. Complement reactivity of cancer patients: measurements by immune hemolysis and immune adherence. Cancer Res. 1967 Dec;27(12):2386–2394. [PubMed] [Google Scholar]
  57. McKneally M. F., Maver C., Kausel H. W. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet. 1976 Feb 21;1(7956):377–379. doi: 10.1016/s0140-6736(76)90212-9. [DOI] [PubMed] [Google Scholar]
  58. Nelson H. S. Delayed hypersensitivity in cancer patients: cutaneous and in vitro lymphocyte response to specific antigens. J Natl Cancer Inst. 1969 May;42(5):765–770. [PubMed] [Google Scholar]
  59. Novogrodsky A., Katchlaski E. Induction of lymphocyte transformation by periodate. FEBS Lett. 1971 Jan 30;12(5):297–300. doi: 10.1016/0014-5793(71)80203-x. [DOI] [PubMed] [Google Scholar]
  60. OLD L. J., BOYSE E. A. IMMUNOLOGY OF EXPERIMENTAL TUMORS. Annu Rev Med. 1964;15:167–186. doi: 10.1146/annurev.me.15.020164.001123. [DOI] [PubMed] [Google Scholar]
  61. Ozawa T., Pluss R., Lacher J., Boedecker E., Guggenheim S., Hammond W., McIntosh R. Endogenous immune complex nephropathy associated with malignancy I. Studies on the nature and immunopathogenic significance of glomerular bound antigen and antibody, isolation and characterization of tumor specific antigen and antibody and circulating immune complexes. Q J Med. 1975 Oct;44(176):523–541. [PubMed] [Google Scholar]
  62. Pierce G. E., DeVald B. L. Leukocyte adherence inhibition as measured by a radioisotopic technique for detection of cell-mediated tumor immunity. Int J Cancer. 1974 Dec 15;14(6):833–839. doi: 10.1002/ijc.2910140618. [DOI] [PubMed] [Google Scholar]
  63. Pines A. A 5-year controlled study of B.C.G. and radiotherapy inoperable lung cancer. Lancet. 1976 Feb 21;1(7956):380–381. doi: 10.1016/s0140-6736(76)90213-0. [DOI] [PubMed] [Google Scholar]
  64. Ray P. K., Thakur V. S., Sundaram K. Antitumour immunity--1. Differential response of neuraminidase-treated and x-irradiated tumour vaccine. Eur J Cancer. 1975 Jan;11(1):1–8. doi: 10.1016/0014-2964(75)90030-4. [DOI] [PubMed] [Google Scholar]
  65. Reynoso G., Chu T. M., Holyoke D., Cohen E., Nemoto T., Wang J. J., Chuang J., Guinan P., Murphy G. P. Carcinoembryonic antigen in patients with different cancers. JAMA. 1972 Apr 17;220(3):361–365. [PubMed] [Google Scholar]
  66. Ribi E. E., Granger D. L., Milner K. C., Strain S. M. Tumor regression caused by endotoxins and mycobacterial fractions. J Natl Cancer Inst. 1975 Nov;55(5):1253–1257. doi: 10.1093/jnci/55.5.1253. [DOI] [PubMed] [Google Scholar]
  67. Sample W. F., Gertner H. R., Jr, Chretien P. B. Inhibition of phytohemagglutinin-induced in vitro lymphocyte transformation by serum from patients with carcinoma. J Natl Cancer Inst. 1971 Jun;46(6):1291–1297. [PubMed] [Google Scholar]
  68. Simmons R. L., Rios A. Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells. Ann Surg. 1972 Aug;176(2):188–194. doi: 10.1097/00000658-197208000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Song C. W., Levitt S. H. Immunotherapy with neuraminidase-treated tumor cells after radiotherapy. Radiat Res. 1975 Dec;64(3):485–491. [PubMed] [Google Scholar]
  70. Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]
  71. Stewart T. H. The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 2. A correlation between the histologic picture of lymphocyte infiltration of the tumor stroma, the presence of such a reaction, and a discussion of the significance of this phenomenon. Cancer. 1969 Jun;23(6):1380–1387. doi: 10.1002/1097-0142(196906)23:6<1380::aid-cncr2820230620>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  72. Sutherland R. M., Inch W. R., McCredie J. A. Phytohemagglutinin (PHA)-induced transformation of lymphocytes from patients with cancer. Cancer. 1971 Mar;27(3):574–578. doi: 10.1002/1097-0142(197103)27:3<574::aid-cncr2820270310>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  73. Takasugi M., Mickey M. R., Terasaki P. I. Studies on specificity of cell-mediated immunity to human tumors. J Natl Cancer Inst. 1974 Dec;53(6):1527–1538. [PubMed] [Google Scholar]
  74. Taylor G., Odili J. L. Histological evidence of tumour rejection after active immunotherapy in human malignant disease. Br Med J. 1972 Apr 22;2(5807):183–188. doi: 10.1136/bmj.2.5807.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Thomas J. W., Lewis H. S., Yuen A. Effect of therapeutic irradiation on lymphocyte transformation in lung cancer. Cancer. 1971 May;27(5):1046–1050. doi: 10.1002/1097-0142(197105)27:5<1046::aid-cncr2820270507>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  76. Vincent R. G., Chu T. M. Carcinoembryonic antigen in patients with carcinoma of the lung. J Thorac Cardiovasc Surg. 1973 Aug;66(2):320–328. [PubMed] [Google Scholar]
  77. Viza D., Louvier M., Phillips J., Boucheix C., Guerin R. A. Solubilization of an antigen associated with certain bronchial tumours. Eur J Cancer. 1975 Nov;11(11):765–770. doi: 10.1016/0014-2964(75)90169-3. [DOI] [PubMed] [Google Scholar]
  78. Watson R. D., Smith A. G., Levy J. G. The detection by immunodiffusion of tumour associated antigenic components in extracts of human bronchongenic carcinoma. Br J Cancer. 1975 Sep;32(3):300–309. doi: 10.1038/bjc.1975.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Wells S. A., Jr, Burdick J. F., Christiansen C., Ketcham A. S., Adkins P. C. Demonstration of tumor-associated delayed cutaneous hypersensitivity reactions in patients with lung cancer and in pateients with carcinoma of the cervix. Natl Cancer Inst Monogr. 1973 Jun;37:197–203. [PubMed] [Google Scholar]
  80. Wolberg W. H., Ansfield F. J. The relation of thymidine labeling index in human tumors in vitro to the effectiveness of 5-fluorouracil chemotherapy. Cancer Res. 1971 Apr;31(4):448–450. [PubMed] [Google Scholar]
  81. Wolf P. L., Vazquez J., Czajkowski N. P., Rosenblatt M. A new method of active immunisation to autologous human tumour tissue. Lancet. 1967 Oct 28;2(7522):905–909. doi: 10.1016/s0140-6736(67)90229-2. [DOI] [PubMed] [Google Scholar]
  82. Woodruff M. F. Tumor inhibitory properties of anaerobic Corynebacteria. Transplant Proc. 1975 Jun;7(2):229–232. [PubMed] [Google Scholar]
  83. Yamamura Y., Azuma I., Taniyama T., Ribi E., Zbar B. Suppression of tumor growth and regression of established tumor with oil-attached mycobacterial fractions. Gan. 1974 Apr;65(2):179–181. [PubMed] [Google Scholar]
  84. al-Sarraf M., Sardesai S., Vaitkevicius V. K. Effect of syngeneic and allogeneic plasma on lymphocytes from cancer patients, patients with non-neoplastic diseases, and normal subjects. Cancer. 1971 Jun;27(6):1426–1432. doi: 10.1002/1097-0142(197106)27:6<1426::aid-cncr2820270624>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES